What Can We Expect From Advanced Accelerator (NASDAQ:AAAP) After Citigroup’s Latest Coverage?


Why Has Citigroup Given Advanced Accelerator (NASDAQ:AAAP) a $32.00 Price Target

In a comprehensive report distributed to Clients today, Citigroup analysts commenced coverage Advanced Accelerator (NASDAQ:AAAP) coverage with Neutral rating, and a $32.00 TP.

The stock closed the day at $26.5 during the previous session. It is down 6.00% since November 7, 2015 and is uptrending. It has outperformed by 7.08% the S&P500.

What Can We Expect From Advanced Accelerator (NASDAQ:AAAP) After Citigroup's Latest Coverage?

Advanced Accelerator Applications SA is a radiopharmaceutical firm that develops, produces and sells molecular nuclear medicine , diagnostic and therapeutic products. The company has a market cap of $1.02 billion. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). It currently has negative earnings. The Firm has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products.

According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.” Get a free copy of the Zacks research report on Advanced Accelerator Application SA(ADR) (AAAP).